Allergan and Adamas agree to 2025 entry for Namzaric generic in Amneal dispute

31 August 2016

Ireland-incorporated Allergan (NYSE: AGN) and its partner Adamas Pharmaceuticals (Nasdaq: ADMS) have come to a settlement with privately-held US generics drugmaker Amneal Pharmaceuticals over a copy of Alzheimer’s disease drug Namzaric (memantine and donepezil hydrochloride).

The settlement relates to a patent infringement litigation brought by the Allergan subsidiary Forest Laboratories and Adamas, a US-based central nervous system (CNS) disorders specialist, in response to Amneal's Abbreviated New Drug Application (ANDA) seeking approval to market generic versions of Allergan's Namzaric.

This drug is a once-daily, fixed-dose combination of memantine hydrochloride, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor indicated for the treatment of moderate to severe dementia of the Alzheimer's type in patients stabilized on 10 mg of donepezil hydrochloride once daily.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK